替米沙坦对血透合并继发性甲亢患者钙磷代谢的影响

Effect of Telmisartan on Calcium-Phosphorus Metabolism in Hemodialysis Patients with Secondary Hyperparathyroidism

目的观察替米沙坦对血透合并继发性甲亢患者钙磷代谢的影响。方法将57例血透合并继发性甲亢患者按治疗方法的不同分为3组,对照组予骨化三醇;在对照组的基础上:治疗1组加服替米沙坦40mg,治疗2组加服替米沙坦80mg,均每天1次。比较3组治疗后的血清甲状旁腺激素(iPTH)、钙、磷水平及不良反应。结果治疗1组、2组血清iPTH、磷水平较对照组降低,血清钙含量较对照组升高(均P<0.05);治疗2组血清iPTH、磷水平较治疗1组降低,血清钙含量较治疗1组升高(均P<0.05)。结论替米沙坦可有效治疗尿毒症患者继发性甲亢。

Objective To observe the effect of telmisartan on calcium-phosphorus metabolism in hemodialysis patients with secondary hyperparathyroidism(SHPT).Methods Fifty-seven hemodialysis patients with SHPT were treated with calcitriol alone(control group)or in combination with telmisartan 40 mg(treatment group 1)or 80 mg(treatment group 2)once daily.Serum intact parathyroid hormone(iPTH),calcium and phosphorus levels and adverse reactions were compared among the three groups.Results Compared with control group,the combined treatment with telmisartan decreased iPTH and phosphorus levels but increased calcium levels(P<0.05).Compared with treatment group 1,the iPTH and phosphorus levels decreased but the calcium levels increased in treatment group 2(P<0.05).Conclusion The telmisartan is effective for SHPT in patients with uremia.